Use your antibodies-online credentials, if available.
抗Mouse (Murine) LMO2 抗体:
抗Rat (Rattus) LMO2 抗体:
抗Human LMO2 抗体:
Human Monoclonal LMO2 Primary Antibody for FACS, ELISA - ABIN1098128
Cubedo, Maurin, Jiang, Lossos, Wright: PRDM1/Blimp1 downregulates expression of germinal center genes LMO2 and HGAL. in The FEBS journal 2011
Show all 2 Pubmed References
Human Monoclonal LMO2 Primary Antibody for IF, IHC (p) - ABIN2475347
Bazan, Scott: Dietary omega-3 fatty acids and accumulation of docosahexaenoic acid in rod photoreceptor cells of the retina and at synapses. in Upsala journal of medical sciences. Supplement 1991
Show all 3 Pubmed References
Human Monoclonal LMO2 Primary Antibody for ChIP, ICC - ABIN259552
Natkunam, Zhao, Mason, Chen, Taidi, Jones, Hammer, Hamilton Dutoit, Lossos, Levy: The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. in Blood 2007
Genome-wide analysis indicated that LMO2 is required at the hemangioblast stage to position the TAL1 (显示 TAL1 抗体)/LMO2/LDB1 (显示 LDB1 抗体) complex to regulatory elements that are important for the establishment of the hematopoietic developmental program.
DNM2 (显示 DNM2 抗体) mutations cooperate with Lmo2 T-cell oncogenes by enhancing IL-7 (显示 IL7 抗体) signalling.
Hhex (显示 HHEX 抗体) regulates Kit to promote radioresistance of self-renewing thymocytes in Lmo2-transgenic mice.
HHEX (显示 HHEX 抗体) is a direct transcriptional target of LMO2 consistent with its concordant gene expression.
GATA2 (显示 GATA2 抗体) and Lmo2 cooperatively regulate VEGF (显示 VEGFA 抗体)-induced angiogenesis and lymphangiogenesis via NRP2 (显示 NRP2 抗体).
a regulatory hierarchy of HOX (显示 MSH2 抗体) control of LMO2 in normal development
Lyl1 is critical for all oncogenic functions of Lmo2, including upregulation of a stem cell-like gene signature, aberrant self-renewal of thymocytes, and subsequent generation of T-cell leukemia.
A model in which the distal control region functions through a chromatin looping mechanism to contact and enhance Lmo2 transcription specifically in erythroid cells.
Studied the solution structure of Lmo2(LIM2 (显示 LHX2 抗体)) /Ldb1 (显示 LDB1 抗体)(LID) complex. Results show modular binding of tandem LIM (显示 PDLIM5 抗体) domains in Lmo2 to tandem linear motifs in Ldb1 (显示 LDB1 抗体) is accompanied by several disorder-to-order transitions/ conformational changes in both proteins.
Studies demonstrate that Etv2 (显示 ETV2 抗体) is expressed during and required for yolk sac (显示 ADCY10 抗体) hematoendothelial development, and that Lmo2 is one of the downstream targets of Etv2 (显示 ETV2 抗体).
LMO2 has a predominantly cytoplasmic location in breast cancer cells. LMO2 interaction with cofilin1 regulates actin cytoskeleton dynamics, promoting tumor cell invasion and metastasis.
These data indicate that Lhx2 (显示 LHX2 抗体) is capable of blocking proliferation of T-ALL-derived cells by both LMO2-dependent and -independent means. We propose Lhx2 (显示 LHX2 抗体) as a new molecular tool for anti-T-ALL drug development.
stromal LMO2 may be responsible for zonal characteristic of Prostate cancer
The transcriptional factor LMO2 regulates endothelial proliferation and angiogenesis in vitro.
This article demonstrates a novel and unexpected function of the LMO2 oncogenic transcription factor in controlling DNA replication that we unravelled via an unbiased proteome-wide screen for LMO2-interacting partners.
Findings suggest that LMO2 loss may be a good predictor for the presence of MYC (显示 MYC 抗体) translocation in large B-cell lymphoma.
FOXP3 (显示 FOXP3 抗体) binds LMO2 in vitro, resulting in decreased interaction between LMO2 and TAL1 (显示 TAL1 抗体), providing a molecular mechanism for FOXP3 (显示 FOXP3 抗体)-mediated transcriptional modulation in T-ALL.
recurrent activating intronic mutations of LMO2, a prominent oncogene (显示 RAB1A 抗体) in T-cell acute lymphoblastic leukemia (T-ALL). Heterozygous mutations were identified in PF-382 and DU.528 T-ALL cell lines in addition to 3.7% of pediatric (6 of 160) and 5.5% of adult (9 of 163) T-ALL patient samples.
Data indicate a novel functional mechanism of LMO2 in facilitating the delivery of actin monomers to the branched microfilament and increasing lamellipodia/filopodia formation in basal-type breast cancer cells.
we demonstrate previously unrecognized mechanisms by which LMO2 alters human T-cell development in vivo; these mechanisms correlate with human T-ALL leukemogenesis.
The transcriptional factor LMO2 regulates endothelial proliferation and angiogenesis in vitro. Furthermore, LMO2 is required for angiogenesis and tissue healing in vivo. Thus, LMO2 is a critical determinant of vascular and tissue regeneration.
a loss-of-function mutation in lmo2, a gene specifically required for hematopoiesis and vascular development, results in failure of optic fissure closure
in the absence of inducers of erythroid or myeloid haematopoiesis, Scl/Tal1 (显示 TAL1 抗体)-Lmo2-induced haemangioblasts differentiate into endothelial cells
Transcriptional regulation of lmo2 promoter during hematopoietic and vascular development in zebrafish is elucidated.
Scl (显示 TAL1 抗体)/Lmo2 complex does not appear to autoregulate, as neither gene's expression is affected by depletion of the other
LMO2 encodes a cysteine-rich, two LIM-domain protein that is required for yolk sac erythropoiesis. The LMO2 protein has a central and crucial role in hematopoietic development and is highly conserved. The LMO2 transcription start site is located approximately 25 kb downstream from the 11p13 T-cell translocation cluster (11p13 ttc), where a number T-cell acute lymphoblastic leukemia-specific translocations occur. Alternative splicing results in multiple transcript variants encoding different isoforms.
, LIM domain only 2 (rhombotin-like 1)
, LIM domain only protein 2
, LIM only 2
, T-cell translocation protein 2
, cysteine-rich protein TTG-2
, T-cell translocation gene 2
, rhombotin 2
, rhombotin-like 1
, LIM domain only-2